Clinical Relevance of Pretransplant HLA Class II Donor-specific Antibodies in Renal Transplantation Patients with Negative T-cell Cytotoxicity Crossmatches
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: We evaluated the clinical relevance of pretransplant donor-specific HLA antibodies (DSA) in renal transplantation patients who had negative T-cell cytotoxicity crossmatches. Methods: From 328 consecutive renal transplant recipients, we selected 28 patients who had positive pretransplant (historical or at the time of transplantation) flow cytometry crossmatches, but negative T-cell cytotoxicity crossmatches at the time of transplantation. The presence of DSA and its level at the time of transplantation were retrospectively tested using Luminex single antigen assays. Results: DSA was present in 16 (57.1%) of 28 patients. Biopsy-proven acute rejection (9 patients) occurred more frequently in patients with DSA than in those without DSA (56.3% vs. 0.0%; P =0.003). The positivity rate of class II DSA was significantly higher in patients with antibody-mediated rejection (AMR) than in those without AMR (100% vs. 21.7%; P = 0.003). However, the positivity rate of class I DSA was not different between the two groups (40% vs. 40.9%). Among patients with class II DSA, those with AMR tended to have higher antibody levels (median fluorescence intensity, MFI) than those without AMR (16,359 vs. 5,910; P =0.056). A cut-off MFI value of 4,487 for class II DSA predicted the occurrence of AMR with good sensitivity and specificity (100% and 87.0%). Conclusions: In patients with negative T-cell cytotoxicity crossmatches, the presence of class II DSA and its level at the time of transplantation were associated with the occurrence of AMR. Pretransplant DSA measurement with Luminex single antigen assay would be useful in renal transplantation.
Abstract
Background: We evaluated the clinical relevance of pretransplant donor-specific HLA antibodies (DSA) in renal transplantation patients who had negative T-cell cytotoxicity crossmatches. Methods: From 328 consecutive renal transplant recipients, we selected 28 patients who had positive pretransplant (historical or at the time of transplantation) flow cytometry crossmatches, but negative T-cell cytotoxicity crossmatches at the time of transplantation. The presence of DSA and its level at the time of transplantation were retrospectively tested using Luminex single antigen assays. Results: DSA was present in 16 (57.1%) of 28 patients. Biopsy-proven acute rejection (9 patients) occurred more frequently in patients with DSA than in those without DSA (56.3% vs. 0.0%; P =0.003). The positivity rate of class II DSA was significantly higher in patients with antibody-mediated rejection (AMR) than in those without AMR (100% vs. 21.7%; P = 0.003). However, the positivity rate of class I DSA was not different between the two groups (40% vs. 40.9%). Among patients with class II DSA, those with AMR tended to have higher antibody levels (median fluorescence intensity, MFI) than those without AMR (16,359 vs. 5,910; P =0.056). A cut-off MFI value of 4,487 for class II DSA predicted the occurrence of AMR with good sensitivity and specificity (100% and 87.0%). Conclusions: In patients with negative T-cell cytotoxicity crossmatches, the presence of class II DSA and its level at the time of transplantation were associated with the occurrence of AMR. Pretransplant DSA measurement with Luminex single antigen assay would be useful in renal transplantation.
참고문헌 (21)
- Gebel HM, "Sensitization and sensitivity: defining the unsensitized patient", Transplantation, 69, pp.1370~1374 (2000)
- Pei R, "Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities", Transplantation, 75, pp.43~49 (2003)
- Lefaucheur C, "Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation", Am J Transplant, 8, pp.324~331 (2008)
- Amico P, "Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads", Transplantation, 87, pp.1681~1688 (2009)
- Eng HS, "Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss", Am J Transplant, 8, pp.2335~2342 (2008)
- Gupta A, "Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?", Transplantation, 85, pp.1200~1204 (2008)
- Aubert V, "Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant", Hum Immunol, 70, pp.580~583 (2009)
- Vlad G, "Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival", Hum Immunol, 70, pp.589~594 (2009)
- Gloor JM, "Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation", Am J Transplant, 10, pp.582~589 (2010)
- Lefaucheur C, "Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation", J Am Soc Nephrol, 21, pp.1398~1406 (2010)
- Reinsmoen NL, "Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy", Transplantation, 86, pp.820~825 (2008)
- Vaidya S, "Improved flow cytometric detection of HLA alloantibodies using pronase: potential implications in renal transplantation", Transplantation, 71, pp.422~428 (2001)
- Racusen LC, "The Banff 97 working classification of renal allograft pathology", Kidney Int, 55, pp.713~723 (1999)
- Racusen LC, "Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection", Am J Transplant, 3, pp.708~714 (2003)
- Pollinger HS, "Ploeger NA, et al. Kidney transplantation in patients with antibodies against donor HLA class II", Am J Transplant, 7, pp.857~863 (2007)
- Stastny P, "Role of immunoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipients", Hum Immunol, 70, pp.600~604 (2009)
- Issa N, "Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels", Transplantation, 86, pp.681~685 (2008)
- Jin YP, "Anti-HLA class I antibody-mediated activation of the PI3K", Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells, 2004, pp.65, 291~302
- Narayanan K, "Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase", Akt pathway, 2004, pp.34, 2303~2312
- Salama AD, "Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody", Am J Transplant, 1, pp.260~269 (2001)
- Warner PR, "HLA density on microparticles versus antibody detection sensitivity: implications for crossmatch prediction", Hum Immunol, 68(S), pp.S28~ (2007)